Skip nav

Alzheimer’s treatment significantly slows disease progression by 35%
Re:Cognition Health Proud to Deliver Donanemab Clinical Trial

Re:Cognition Health, a pioneering brain and mind clinic specialising in the delivery of clinical trials, is thrilled by the promising results of the TRAILBLAZER-ALZ 2 study. The trial included 1,736 international participants, 62 from the UK who all participated through Re:Cognition Health’s UK centres in London, Guildford and Birmingham.

The phase 3 randomized, double-blind, placebo-controlled clinical trial investigated the efficacy of donanemab in slowing the progression of Alzheimer’s disease in patients with early symptoms over an 18-month period.

The results of the TRAILBLAZER-ALZ 2 study show that donanemab slowed cognitive
decline by 35% compared to the placebo. Functional decline, relating to the ability to perform
normal daily living such as activities managing finances,...

Read full release